Checkpoint Therapeutics, Inc.

NasdaqCM:CKPT Voorraadrapport

Marktkapitalisatie: US$158.0m

Checkpoint Therapeutics Beheer

Beheer criteriumcontroles 3/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

James Oliviero

Algemeen directeur

US$1.6m

Totale compensatie

Percentage CEO-salaris38.7%
Dienstverband CEO9.1yrs
Eigendom CEO4.3%
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuur6.1yrs

Recente managementupdates

Recent updates

We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Sep 20
We're A Little Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint: Strong Data, But Comes With Risks

Sep 08

Checkpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01M

Aug 12

Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

May 18
Is Checkpoint Therapeutics (NASDAQ:CKPT) In A Good Position To Deliver On Growth Plans?

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

Apr 18

Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Feb 15
Companies Like Checkpoint Therapeutics (NASDAQ:CKPT) Are In A Position To Invest In Growth

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Jan 28

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

Nov 26

Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

Oct 30
Checkpoint Therapeutics (NASDAQ:CKPT) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Jul 17
We're Not Very Worried About Checkpoint Therapeutics' (NASDAQ:CKPT) Cash Burn Rate

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

Jul 14

Checkpoint Therapeutics (CKPT) Investor Presentation - Slideshow

Jun 21

Checkpoint surges 24% on B. Riley buy initiation, 567% upside potential

Jun 09

It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

Jun 02
It's Unlikely That Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) CEO Will See A Huge Pay Rise This Year

The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Mar 11
The Checkpoint Therapeutics (NASDAQ:CKPT) Share Price Is Up 141% And Shareholders Are Boasting About It

Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?

Feb 06
Have Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Insiders Been Selling Their Stock?

Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?

Jan 27
Do Institutions Own Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares?

Analyse CEO-vergoeding

Hoe is James Oliviero's beloning veranderd ten opzichte van Checkpoint Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$52m

Dec 31 2023US$2mUS$636k

-US$52m

Sep 30 2023n/an/a

-US$54m

Jun 30 2023n/an/a

-US$59m

Mar 31 2023n/an/a

-US$56m

Dec 31 2022US$2mUS$594k

-US$63m

Sep 30 2022n/an/a

-US$71m

Jun 30 2022n/an/a

-US$72m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$2mUS$540k

-US$57m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$2mUS$515k

-US$23m

Sep 30 2020n/an/a

-US$22m

Jun 30 2020n/an/a

-US$22m

Mar 31 2020n/an/a

-US$22m

Dec 31 2019US$2mUS$480k

-US$25m

Sep 30 2019n/an/a

-US$28m

Jun 30 2019n/an/a

-US$32m

Mar 31 2019n/an/a

-US$33m

Dec 31 2018US$2mUS$450k

-US$36m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$27m

Mar 31 2018n/an/a

-US$27m

Dec 31 2017US$645kUS$430k

-US$23m

Compensatie versus markt: James's total compensation ($USD1.64M) is about average for companies of similar size in the US market ($USD1.48M).

Compensatie versus inkomsten: James's compensation has been consistent with company performance over the past year.

CEO

James Oliviero (48 yo)

9.1yrs

Tenure

US$1,641,591

Compensatie

Mr. James F. Oliviero, III, CFA has been the Chief Executive Officer and President of Checkpoint Therapeutics, Inc. since October 16, 2015 and also has been its Director since October 15, 2018. Mr. Olivier...

Bestuursleden

NaamPositieTenureCompensatieEigendom
James Oliviero
President6.1yrsUS$1.64m4.31%
$ 6.8m
Michael Weiss
Chairman of the Board9.7yrsUS$110.00k0.25%
$ 393.7k
Lindsay Rosenwald
Non-Executive Director10yrsUS$100.00k0.29%
$ 463.9k
Wayne Marasco
Chairman of Scientific Advisory Board9.7yrsgeen gegevensgeen gegevens
Roy Steven Herbst
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens
Neil Herskowitz
Independent Director9.3yrsUS$110.00k0.26%
$ 411.3k
Christian Béchon
Independent Director6.1yrsUS$100.00k0.25%
$ 402.0k
Barry Salzman
Independent Director8.8yrsUS$100.00k0.26%
$ 411.3k
Bruce Johnson
Member of Scientific Advisory Board3.7yrsgeen gegevensgeen gegevens
F. Hodi
Member of Scientific Advisory Board3.7yrsgeen gegevensgeen gegevens
Emily Ruiz
Member of Scientific Advisory Board3.7yrsgeen gegevensgeen gegevens
David Miller
Member of Scientific Advisory Board3.7yrsgeen gegevensgeen gegevens

6.1yrs

Gemiddelde duur

63.5yo

Gemiddelde leeftijd

Ervaren bestuur: CKPT's board of directors are considered experienced (6.1 years average tenure).